Gap junction-mediated bystander effect in primary cultures of human malignant gliomas with recombinant expression of the HSVtk gene

Experimental Cell Research

Volumn 284, Issue 2, 2003, Pages 183-193

  Asklund, Thomas ^a   Appelskog, Ioulia B ^a   Ammerpohl, Ole ^a   Langmoen, Iver A ^a   Dilber, M Sirac ^b   Aints, Alar ^b   Ekström, Tomas J ^a   Almqvist, Per M ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bystander effect; Connexin 43; Ganciclovir; Gap junction; Gene therapy; HSVtk; Malignant glioma

Indexed keywords

CONNEXIN 43; FLUORESCENT DYE; GANCICLOVIR; GAP JUNCTION PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCYRRHETINIC ACID DERIVATIVE; NESTIN; PROTEIN S 100; RECOMBINANT ENZYME; THYMIDINE KINASE; TUMOR MARKER; VIMENTIN; VIRUS ENZYME;

ARTICLE; BYSTANDER EFFECT; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; GAP JUNCTION; GENE EXPRESSION; GENETIC TRANSFECTION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNODETECTION; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SUICIDE GENE THERAPY; TUMOR BIOPSY; WESTERN BLOTTING;

HERPES; HUMAN HERPESVIRUS 1;

EID: 0347926503     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-4827(02)00052-6     Document Type: Article

References (43)

1. Laws E.R. Jr. Central nervous system tumors what have we learned and where are we heading . CA-Cancer J. Clin. 48:(6):1998;327-329.
2. Shapiro W.R. Current therapy for brain tumors back to the future . Neurol. Rev. 56:1999;429-432.
3. Prados M.D., Berger M.S., Wilson C.B. Primary central nervous system tumors advances in knowledge and treatment . CA-Cancer J. Clin. 48:(6):1998;331-360.
4. Moolten F.L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes paradigm for a prospective cancer control strategy . Cancer Res. 46:1986;5276-5281.
5. Freeman S.M., Whartenby K.A., Freeman J.L., Abboud C.N., Marrogi A.J. In situ use of suicide genes for cancer therapy. Semin. Oncol. 23:1996;31-45.
6. Dilber M.S., Abedi M.R., Christensson B., Björkstrand B., Kidder G.M., Naus C.C., Gahrton G., Smith C.I. Gap junctions promote the bystander effect of Herpes Simplex Virus thymidine kinase in vivo. Cancer Res. 57:1997;1523-1528.
7. Freeman S.M., Abboud C.N., Whartenby K.A., Packman C.H., Koeplin D.S., Moolten F.L., Abraham G.N. The "bystander effect:" tumor regression when a fraction of the tumor mass is genetically modified . Cancer Res. 53:1993;5274-5283.
8. Ram Z., Culver K.W., Walbridge S., Blaese R.M., Oldfield E.H. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 53:1993;83-88.
9. Bi W.L., Parysek L.M., Warnick R., Stambrook P.J. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSVtk retroviral gene therapy. Hum. Gene Ther. 4:1993;725-731.
10. Fick J., Barker F.G.N., Dazin P., Westphale E.M., Beyer E.C., Israel M.A. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc. Natl. Acad. Sci. USA. 92:1995;11071-11075.
11. Mesnil M., Piccoli C., Tiraby G., Willecke K., Yamasaki H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase is mediated by connexins. Proc. Natl. Acad. Sci. USA. 93:1996;1831-1835.
12. Elshami A.A., Saavedra A., Zhang H., Kucharzuk J.C., Spray D.C., Fishman G.I., Amin K.M., Kaiser L.R., Albelda S.M. Gap junctions play a role in the "bystander effect" of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther. 3:1996;85-92.
13. Dilber M.S., Smith C.I. Suicide genes and bystander killing local and distant effects . Gene Ther. 4:(4):1997;273-274.
14. Caruso M., Panis Y., Gagandeep S., Houssin D., Salzmann J.L., Klatzmann D. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc. Natl. Acad. Sci. USA. 90:1993;7024-7028.
15. Vile R.G., Nelson J.A., Castleden S., Chong H., Hart I.R. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. 54:1994;6228-6234.
16. Barba D., Hardin J., Sadelain M., Gage F.H. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc. Natl. Acad. Sci. USA. 91:1994;4348-4352.
17. Ramesh R., Marrogi A.J., Munshi A., Freeman S.M. In vivo analysis of the "bystander effect:" a cytokine cascade . Exp. Hematol. 24:1996;829-838.
18. Samejima Y., Maruelo D. "Bystander killing" induces apoptosis and is inhibited by forskolin. Gene Ther. 2:1995;50-58.
19. Beyer E.C. Gap junctions. Int. Rev. Cytol. 137C:1993;1-37.
20. Paul D.L. New functions for gap junctions. Curr. Opin. Cell Biol. 7:1995;665-672.
21. Yamasaki H., Naus C.C. Role of connexin genes in growth control. Carcinogenesis. 17:(6):1996;1199-1213.
22. Huang R.-P., Hossain M., Sehgal A., Boynton A. Reduced connexin 43 expression in high-grade human brain glioma cells. J. Surg. Oncol. 70:1999;21.
23. Estin D., Li M., Spray D., Wu J.K. Connexins are expressed in primary brain tumors and enhance the bystander effect in gene therapy. Neurosurgery. 44:1999;361-368.
24. Shinoura N., Chen L., Wani M.A., Kim Y.G., Larson J.J., Warnick R.E., Simon M., Menon A.G., Bi W.L., Stambrook P.J. Protein and messenger RNA expression of connexin 43 in astrocytomas implications in brain tumor gene therapy . J. Neurosurg. 84:1996;839-846.
25. Zhang W., Couldwell W.T., Simard M.F., Song H., Liu J.H., Nedergaard M. Direct gap junction communication between malignant glioma cells and astrocytes. Cancer Res. 59:1999;1994-2003.
26. Goldberg G.S., Bechberger J.F., Naus C.C. A pre-loading method of evaluating gap junctional communication by fluorescent dye. Biotechniques. 18:1995;490-497.
27. Touraine R.L., Ishii-Morita H., Ramsey W., Blaese R.M. The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication. Gene Ther. 5:1998;1705-1711.
28. Guo Y., Martinez-Williams C., Gilbert K.A., Rannels D.E. Inhibition of gap junction communication in alveolar epithelial cells by 18α-glycyrrhetinic acid. Am. J. Physiol. 276:1999;1018-1026.
29. Robe P.A., Princen F., Martin D., Malgrange B., Stevenaert A., Moonen G., Gielen J., Merville M., Bours V. Pharmacological modulation of the bystander effect in the Herpes Simplex Virus thymidine kinase/ganciclovir gene therapy system. Biochem. Pharmacol. 60:1999;241-249.
30. Lund-Johansen M., Engebraaten O., Bjerkvig R., Laerum O.D. Invasive glioma cells in tissue culture. Anticancer Res. 10:1990;1135-1152.
31. Rutka J.T., Giblin J.R., Doughherty D.Y., Liu H.C., Mc Culloch J.R., Bell C.W., Stern R.S., Wilson C.B., Rosenblum M.L. Establishment and characterization of five cell lines derived from human malignant gliomas. Acta Neuropathol. 75:1987;92-103.
32. Hood C.J., Parham D.M. A simple method of tumour culture. Pathol. Res. Pract. 194:1998;177-188.
33. Kaaijk A.P., Troost D., Das P.K., Leenstra S., Bosch D.A. Long-term culture of organotypic multicellular glioma spheroids a good culture model for studying gliomas . Neuropathol. Appl. Neurobiol. 21:1995;386-391.
34. Rutka J.T., Ivanchuk S., Mondal S., Taylor M., Sakai K., Dirks P., Jun P., Jung S., Becker L.E., Ackerley C. Co-expression of nestin and vimentin intermediate filaments in invasive human astrocytoma cells. Int. J. Dev. Neurosci. 17:(5-6):1999;503-515.
35. Kumar N.M., Gilula N.B. The gap junction communication channel. Cell. 84:1996;381-388.
36. Rose C.R., Ranson B.R. Gap junctions equalize intracellular Na+ concentration in astrocytes. GLIA. 20:(4):1997;299-307.
37. Davidson J.S., Baumgarten I.M. Glycyrrhetinic acid derivatives a novel class of inhibitors of gap junction intercellular communication. Structure-activity relationships . J. Pharmacol. Exp. Ther. 246:1988;1104-1107.
38. Goldberg G.S., Moreno A.P., Bechberger J.F., Hearn S.S., Shivers R.R., Mac Phee D.J., Zhang Y.C., Naus C.C. Evidence that disruption of connexon particle arrangements in gap junction plaques is associated with inhibition of gap junctional communication by a glycyrrhetinic acid derivative. Exp. Cell Res. 222:1996;48-53.
39. Guan X., Wilson S., Schlender K.K., Ruch R.J. Gap junction disassembly and connexin 43 dephosphorylation induced by 18-beta glycyrrhetinic acid. Mol. Carcinog. 16:1996;157-164.
40. Cirenei N., Colombo B.M., Mesnil M., Benedetti S., Yamasaki H., Finocchiaro G. In vitro and in vivo effects of retrovirus-mediated transfer of the connexin 43 gene in malignant gliomas consequences for HSVtk/GCV anticancer gene therapy . Gene Ther. 5:1998;1221-1226.
41. Duflot-Dancer A., Piccoli C., Rolland A., Yamasaki H., Mesnil M. Long-term connexin-mediated bystander effect in highly tumorigenic human cells in vivo in herpes simplex virus thymidine kinase/ganciclovir gene therapy. Gene Ther. 5:1998;1372-1378.
42. Sturtz F.G., Waddell K., Shulok J., Chen X., Caruso M., Sanson M., Snodgrass H.R., Platika D. Variable efficiency of the thymidine kinase/ganciclovir system in human glioblastoma cell lines implications for gene therapy . Hum. Gene Ther. 8:1997;1945-1953.
43. Kokoris M.S., Sabo P., Adman E.T., Black M.E. Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant. Gene Ther. 6:1999;1415-1426.